Ovarian tumors with low 53BP1 expression show improved responsiveness to immune checkpoint blockade (ICB), making 53BP1 loss a potential biomarker for predicting ICB therapy response (29). The gene discussed is TP53BP1; the disease is ovarian neoplasm.